177Lu-HER3 ARC / Actinium - LARVOL DELTA

Novel HER3 targeting antibody radioconjugates, 225Ac-HER3 ARC and 177Lu-HER3 ARC, exhibit potent antitumor efficacy in HER3-positive solid tumors (AACR 2023) - "In this study, both 225Ac-HER3 ARC and 177Lu-HER3 ARC demonstrated significant antitumor activity against HER3-expressing tumors in a dose-dependent manner. The HER3 targeted radiotherapy approach that we have undertaken could potentially overcome the limitations of current solid tumor therapies in resistance settings and warrants further evaluation in patients with HER3-expressing tumors."

Clinical • Kidney Cancer • Oncology • Renal Cell Carcinoma • Solid Tumor • EGFR

Actinium Highlights First-In-Class HER3 Targeted Radiotherapy Data Demonstrating Potent Anti-Cancer Activity of in Ovarian and Colorectal Cancer Models at the AACR Annual Meeting (PRNewswire) - "Actinium Pharmaceuticals...announces encouraging preclinical proof of concept data at a poster presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting.... A single dose of HER3-ARC, conjugated to either Actinium-225 (p<0.0001) or Lutetium-177 (p<0.0001) showed highly significant reductions in tumor burden in a preclinical ovarian cancer model compared to bevacizumab, an anti-VEGF monoclonal antibody indicated in ovarian cancer. Promising antitumor activity displayed in a preclinical model of colorectal cancer, a highly aggressive malignancy, including a significant reduction in tumor volume (p<0.0001) when dosed with 225Ac-HER3-ARC."

Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor

Actinium to Showcase First-In-Class Targeted Radiotherapies in Two Presentations at the 2023 AACR Annual Meeting (PRNewswire) - "Actinium Pharmaceuticals, Inc...announced today that two abstracts have been accepted for presentation at the American Association for Cancer Research (AACR) 2023 Annual Meeting being held April 14 - 19, 2023 in Orlando, Florida....Accepted presentations will feature data that continue to support potent anti-tumor activity of Actinium's first-in-class HER3 radiotherapy in preclinical models of cancers with unmet therapeutic needs, as well as new data evaluating novel applications of Actimab-A to selectively deplete CD33+ myeloid-derived suppressor cells (MDSCs), a highly immunosuppressive cell type that is a major component of the tumor microenvironment."

Clinical data • Preclinical • Colorectal Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Oncology • Ovarian Cancer • Solid Tumor